The company is looking at bolstering its overseas presence.

New Delhi: The Indian drug firm Lupin is looking at various global markets like US, Latin America and Europe to expand its overseas presence. The company is most likely to acquire companies in markets like US, Latin America, Russia, Turkey, Japan and China.

The company will continue to be on a lookout for meaningful targets in the inhalation complex injectables and derma space. It may be noted here that its global markets (excluding India) accounted for close to 75 per cent of the total revenues of the company, which stood at over Rs 11,000 crore.

The company has already entered the Mexican market and would continue to look for acquisitions in key LatAm markets like Brazil. The company expects the US to be a strong growth driver in the coming year as well. The US market contributes close to 44 per cent of the overall sales of the company and it expects the product approvals to pick up in the US in the coming year.